share_log

Avalo Therapeutics | 8-K: Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics | 8-K: Avalo Reports Second Quarter 2024 Financial Results and Provides Business Updates

Avalo Therapeutics | 8-K:Avalo公佈2024年第二季度財務業績並提供業務最新情況
美股SEC公告 ·  2024/08/12 19:05

牛牛AI助理已提取核心訊息

Avalo Therapeutics reported Q2 2024 financial results with $93.4 million in cash and cash equivalents as of June 30, 2024, projecting runway into 2027. The company recorded a net loss of $22.8 million for the first half of 2024, up $4.7 million YoY, primarily due to $27.6 million in acquired IPR&D expenses from the AlmataBio acquisition.The company announced plans to initiate the Phase 2 LOTUS Trial of AVTX-009, an anti-IL-1β monoclonal antibody, for hidradenitis suppurativa treatment in H2 2024, following IND activation in July. Additionally, Avalo aims to develop AVTX-009 in at least one other chronic inflammatory indication.Key management appointments include Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer. Operating expenses increased by $25.3 million, while a $21.7 million increase in other income was largely attributed to warrant liability fair value changes offsetting private placement losses.
Avalo Therapeutics reported Q2 2024 financial results with $93.4 million in cash and cash equivalents as of June 30, 2024, projecting runway into 2027. The company recorded a net loss of $22.8 million for the first half of 2024, up $4.7 million YoY, primarily due to $27.6 million in acquired IPR&D expenses from the AlmataBio acquisition.The company announced plans to initiate the Phase 2 LOTUS Trial of AVTX-009, an anti-IL-1β monoclonal antibody, for hidradenitis suppurativa treatment in H2 2024, following IND activation in July. Additionally, Avalo aims to develop AVTX-009 in at least one other chronic inflammatory indication.Key management appointments include Dr. Mittie Doyle as Chief Medical Officer and Paul Varki as Chief Legal Officer. Operating expenses increased by $25.3 million, while a $21.7 million increase in other income was largely attributed to warrant liability fair value changes offsetting private placement losses.
Avalo Therapeutics報告了2024年第二季度財務結果,截至2024年6月30日擁有9,340萬美元的現金及現金等價物,預計可使用到2027年。公司在2024年上半年錄得淨虧損2,280萬美元,同比增長470萬美元,主要由於從AlmataBio收購中產生的2,760萬美元知識產權與研發費用。公司宣佈計劃於2024年下半年啓動AVTX-009的第二階段LOTUS試驗,AVTX-009是一種抗IL-1β單克隆抗體,用於治療骯腩溼疣,IND將於7月啓動。此外,Avalo還計劃在至少一個其他慢性炎症適應症中開發AVTX-009。關鍵管理任命包括Dr. Mittie Doyle擔任首席醫療官,Paul Varki擔任首席法律官。營業費用增加了2,530萬美元,而其他收入增長2,170萬美元主要歸因於權證負債公允價值變動抵消了定向增發的損失。
Avalo Therapeutics報告了2024年第二季度財務結果,截至2024年6月30日擁有9,340萬美元的現金及現金等價物,預計可使用到2027年。公司在2024年上半年錄得淨虧損2,280萬美元,同比增長470萬美元,主要由於從AlmataBio收購中產生的2,760萬美元知識產權與研發費用。公司宣佈計劃於2024年下半年啓動AVTX-009的第二階段LOTUS試驗,AVTX-009是一種抗IL-1β單克隆抗體,用於治療骯腩溼疣,IND將於7月啓動。此外,Avalo還計劃在至少一個其他慢性炎症適應症中開發AVTX-009。關鍵管理任命包括Dr. Mittie Doyle擔任首席醫療官,Paul Varki擔任首席法律官。營業費用增加了2,530萬美元,而其他收入增長2,170萬美元主要歸因於權證負債公允價值變動抵消了定向增發的損失。

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。

    聲明

    本頁的譯文內容由軟件翻譯。富途將竭力但卻不能保證翻譯內容之準確和可靠,亦不會承擔因任何不準確或遺漏而引起的任何損失或損害。